Companies /Healthcare

Celldex Therapeutics Inc

NASDAQ: CLDX Biotechnology
$40.46
▼ $0.11 (−0.27%) today
Markets closed · 10:03pm ET

CLDX Coverage

Page 2
10:15am ET
Health and Healthcare

Key Movers to Look for Ahead of ASCO

The American Society of Clinical Oncology (ASCO) is gearing up for its annual meeting. At this meeting, cancer drug developers will share the results from their most recent drug trials.

Chris Lange
10:20am ET
Health and Healthcare

8 Stocks on the Move After ASCO Cancer Abstracts

ASCO has just released the abstracts for its exhibitors ahead of the conference. For investors and analysts, sometimes winners or losers from the meeting can be divined ahead of time by these…

Chris Lange
4:04pm ET
Investing

The 52-Week Low Club for Friday

March 11, 2016: Here are four stocks trading with heavy volume among 16 equities making new 52-week lows in Friday’s session. Celldex Therapeutics Inc. (NASDAQ: CLDX) posted a new 52-week low on…

Paul Ausick
4:04pm ET
Investing

The 52-Week Low Club for Wednesday

March 9, 2016: Here are four stocks trading with heavy volume among 26 equities making new 52-week lows in Wednesday’s session. Unisys Corp. (NYSE: UIS) fell by nearly 28% on Wednesday to…

Paul Ausick
4:04pm ET
Investing

The 52-Week Low Club for Tuesday

March 8, 2016: Here are four stocks trading with heavy volume among 18 equities making new 52-week lows today. Performance Sports Group Ltd. (NYSE: PSG) fell by nearly 66% on Tuesday to…

Paul Ausick
4:04pm ET
Investing

The 52-Week Low Club for Monday

March 7, 2016: Here are four stocks trading with heavy volume among 12 equities making new 52-week lows today. Celldex Therapeutics Inc. (NASDAQ: CLDX) posted a new 52-week low on Monday. Shares…

Paul Ausick
11:40am ET
Health and Healthcare

Is This the Start of the Final Implosion at Celldex?

Celldex Therapeutics Inc. (NASDAQ: CLDX) got burned in Monday’s regular trading session and ultimately saw its shares fall by over 50%. The reasoning behind this? The independent Data Safety and Monitoring Board…

Chris Lange